Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 14/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 13/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757439 | 0.93 | NR1H4 (0.48) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6759582 | 0.91 | NR1H4 (0.60) | NR1H4LTB4RLTB4R2C5AR1 | |
| SCHEMBL6757622 | 0.84 | NR1H4 (0.51) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL8568257 | 0.83 | NR1H4 (0.52) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6899767 | 0.82 | NR1H4 (0.46) | NR1H4LTB4RLTB4R2C5AR1 | |
| SCHEMBL6759039 | 0.82 | NR1H4 (0.51) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6757535 | 0.80 | LTB4R (0.50) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL8563732 | 0.78 | NR1H4 (0.49) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6759116 | 0.78 | NR1H4 (0.47) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6758945 | 0.77 | NR1H4 (0.49) | NR1H4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-12-09 | — | — | US | disclosed |
| US-6770259-B2 | ADMINISTEING RADIOLABELED LEUKOTRIENE (LTB4) BINDING AGENT AND A RADIOLABELED PERFUSION IMAGING AGENT; CONCURRENTLY DETECTING THE RADIOLABELED LTB4 BINDING AGENT BOUND AT THE LTB4 RECEPTOR AND THE RADIOLABELED PERFUSION IMAGING AGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| WO-2003099810-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1347784-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | Bristol-Myers Squibb Pharma Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-03 | — | — | US | disclosed |
| EP-0999856-B1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1293214-A2 | LTB4 antagonists and radiopharmaceuticals for imaging infection and inflammation | Bristol-Myers Squibb Pharma Company (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | BARRETT JOHN A (US) | 2003-01-09 | — | — | US | disclosed |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LANTHEUS MEDICAL IMAGING, INC. | 2003-01-02 | — | — | US | disclosed |
| US-6416733-B1 | RADIOPHARMACEUTICALS BIND IN VIVO TO THE LEUKOTRIENE B4 (LTB4) RECEPTOR ON THE SURFACE OF LEUKOCYTES WHICH ACCUMULATE AT THE SITE OF INFECTION AND INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-09 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-0999856-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | Du Pont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1998015295-A2 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030124053-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | NR1H4 169/4885LTB4R 1/4885LTB4R2 2/4885 |
| US-20030007927-A1 | Radiopharmaceuticals for imaging infection and inflammation | LTB4R, LTB4R2, LTA4H | NR1H4 169/4885LTB4R 1/4885LTB4R2 2/4885 |
| US-20040247523-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | NR1H4 390/4885LTB4R 1/4885LTB4R2 2/4885 |
| US-20030003049-A1 | Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation | LTB4R, LTB4R2, FABP3 | NR1H4 390/4885LTB4R 1/4885LTB4R2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.